Literature DB >> 28941550

Interaction prediction in structure-based virtual screening using deep learning.

Adam Gonczarek1, Jakub M Tomczak2, Szymon Zaręba3, Joanna Kaczmar2, Piotr Dąbrowski4, Michał J Walczak5.   

Abstract

We introduce a deep learning architecture for structure-based virtual screening that generates fixed-sized fingerprints of proteins and small molecules by applying learnable atom convolution and softmax operations to each molecule separately. These fingerprints are further non-linearly transformed, their inner product is calculated and used to predict the binding potential. Moreover, we show that widely used benchmark datasets may be insufficient for testing structure-based virtual screening methods that utilize machine learning. Therefore, we introduce a new benchmark dataset, which we constructed based on DUD-E, MUV and PDBBind databases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Keywords:  DUD-E; Deep learning; Graph convolution; MUV; Neural fingerprint; PDBBind; Virtual screening

Mesh:

Substances:

Year:  2017        PMID: 28941550     DOI: 10.1016/j.compbiomed.2017.09.007

Source DB:  PubMed          Journal:  Comput Biol Med        ISSN: 0010-4825            Impact factor:   4.589


  13 in total

1.  Data Set Augmentation Allows Deep Learning-Based Virtual Screening to Better Generalize to Unseen Target Classes and Highlight Important Binding Interactions.

Authors:  Jack Scantlebury; Nathan Brown; Frank Von Delft; Charlotte M Deane
Journal:  J Chem Inf Model       Date:  2020-08-04       Impact factor: 4.956

2.  Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics.

Authors:  Isabela de Souza Gomes; Charles Abreu Santana; Leandro Soriano Marcolino; Leonardo Henrique França de Lima; Raquel Cardoso de Melo-Minardi; Roberto Sousa Dias; Sérgio Oliveira de Paula; Sabrina de Azevedo Silveira
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.752

Review 3.  Applications of artificial intelligence to drug design and discovery in the big data era: a comprehensive review.

Authors:  Neetu Tripathi; Manoj Kumar Goshisht; Sanat Kumar Sahu; Charu Arora
Journal:  Mol Divers       Date:  2021-06-10       Impact factor: 2.943

4.  Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.

Authors:  Kushagra Kashyap; Mohammad Imran Siddiqi
Journal:  Mol Divers       Date:  2021-07-19       Impact factor: 3.364

Review 5.  Artificial intelligence to deep learning: machine intelligence approach for drug discovery.

Authors:  Rohan Gupta; Devesh Srivastava; Mehar Sahu; Swati Tiwari; Rashmi K Ambasta; Pravir Kumar
Journal:  Mol Divers       Date:  2021-04-12       Impact factor: 3.364

6.  Hidden bias in the DUD-E dataset leads to misleading performance of deep learning in structure-based virtual screening.

Authors:  Lieyang Chen; Anthony Cruz; Steven Ramsey; Callum J Dickson; Jose S Duca; Viktor Hornak; David R Koes; Tom Kurtzman
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

7.  Discovery of small-molecule inhibitors targeting the ribosomal peptidyl transferase center (PTC) of M. tuberculosis.

Authors:  Benjamin Tam; Dror Sherf; Shira Cohen; Sarah Adi Eisdorfer; Moshe Perez; Adam Soffer; Dan Vilenchik; Sabine Ruth Akabayov; Gerhard Wagner; Barak Akabayov
Journal:  Chem Sci       Date:  2019-08-06       Impact factor: 9.825

8.  Collaborative Approach between Explainable Artificial Intelligence and Simplified Chemical Interactions to Explore Active Ligands for Cyclin-Dependent Kinase 2.

Authors:  Tomomi Shimazaki; Masanori Tachikawa
Journal:  ACS Omega       Date:  2022-03-18

Review 9.  Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases.

Authors:  Ahmet Sureyya Rifaioglu; Heval Atas; Maria Jesus Martin; Rengul Cetin-Atalay; Volkan Atalay; Tunca Doğan
Journal:  Brief Bioinform       Date:  2019-09-27       Impact factor: 11.622

10.  Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature.

Authors:  Yoosup Chang; Hyejin Park; Hyun-Jin Yang; Seungju Lee; Kwee-Yum Lee; Tae Soon Kim; Jongsun Jung; Jae-Min Shin
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.